The Vanguard Group 13D and 13G filings for Intra-Cellular Therapies, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-13 5:08 pm Purchase | 2023-12-29 | 13G | Intra-Cellular Therapies, Inc. ITCI | The Vanguard Group | 9,094,302 9.450% | 775,053 (+9.32%) | Filing |
| 2023-02-09 11:22 am Purchase | 2022-12-30 | 13G | Intra-Cellular Therapies, Inc. ITCI | The Vanguard Group | 8,319,249 8.780% | 1,443,048 (+20.99%) | Filing |
| 2022-02-10 08:17 am Purchase | 2021-12-31 | 13G | Intra-Cellular Therapies, Inc. ITCI | The Vanguard Group | 6,876,201 8.440% | 394,857 (+6.09%) | Filing |
| 2021-02-10 11:03 am Purchase | 2020-12-31 | 13G | Intra-Cellular Therapies, Inc. ITCI | The Vanguard Group | 6,481,344 8.090% | 2,261,754 (+53.60%) | Filing |
| 2020-02-12 11:01 am Purchase | 2019-12-31 | 13G | Intra-Cellular Therapies, Inc. ITCI | The Vanguard Group | 4,219,590 7.630% | 285,660 (+7.26%) | Filing |